Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 9/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556256 | 0.95 | BTK (0.41) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL554830 | 0.93 | BTK (0.40) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL556933 | 0.92 | BTK (0.40) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL556491 | 0.92 | BTK (0.40) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL3977507 | 0.91 | BTK (0.43) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL556239 | 0.89 | BTK (0.41) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL5437210 | 0.89 | MAP4K4 (0.46) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL5435581 | 0.89 | BTK (0.42) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL556164 | 0.89 | MAP4K4 (0.46) | BTKJAK3DPP4MAP4K4LCK | |
| SCHEMBL4635505 | 0.88 | BTK (0.41) | BTKJAK3DPP4MAP4K4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569574-B2 | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | BTK 3668/4885JAK3 2454/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.